Connor, Clark & Lunn Investment Management (CC&L)
TNYA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Tenaya Therapeutics TNYA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,371
Closed -$107K – 1695
2024
Q1 		$107K Buy
20,371
+5,942
+41% +$28.4K ﹤0.01% 1461
2023
Q4 		$46.8K Buy
+14,429
New +$31.1K ﹤0.01% 1340

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TNYA Position: Q2 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Tenaya Therapeutics (TNYA) in Q2 2024, closing a stake of 20,371 shares — an estimated $107K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TNYA in Q4 2023 and held it in 2 quarters. The position peaked at $107K in Q1 2024. 96 funds tracked by Wall St. Rank hold TNYA as of Q2 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Tenaya Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 20,371 Tenaya Therapeutics shares in Q2 2024, an estimated $107K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Tenaya Therapeutics in Q4 2023 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Tenaya Therapeutics position peaked at $107K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2024, filed 9 Aug 2024.